Turn Therapeutics Inc. (NASDAQ:TTRX) Given Average Rating of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Of five covering firms, two rate Turn Therapeutics a sell, one a hold, one a buy and one a strong buy. The average 12-month price target is $9.00.
• Shares rose 6.8% to $13.55 in Monday trading, well above the consensus target, but remain volatile, with a 52-week range of $2.57 to $26.50.
• Turn Therapeutics reported a quarterly loss of $0.20 per share, and analysts expect a full-year loss of $0.40 per share. Several institutional investors, including BlackRock and Millennium Management, recently initiated positions.

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) have received a consensus recommendation of "Hold" from the five research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $9.00.

A number of research analysts have recently issued reports on the company. Wall Street Zen raised Turn Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday. Zacks Research raised shares of Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. WBB Securities reissued a "sell" rating and issued a $10.00 target price on shares of Turn Therapeutics in a research note on Monday. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Finally, Weiss Ratings cut shares of Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th.

Turn Therapeutics Trading Up 6.8%

NASDAQ TTRX traded up $0.86 during trading hours on Monday, reaching $13.55. The company's stock had a trading volume of 85,580 shares, compared to its average volume of 55,308. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $26.50. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market cap of $403.80 million and a P/E ratio of -46.14. The firm has a fifty day simple moving average of $9.71 and a 200-day simple moving average of $6.28.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities analysts forecast that Turn Therapeutics will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several large investors have recently modified their holdings of TTRX. Ieq Capital LLC purchased a new position in Turn Therapeutics during the second quarter worth $1,660,000. Millennium Management LLC bought a new position in shares of Turn Therapeutics during the fourth quarter valued at approximately $377,000. Wellington Shields & Co. LLC purchased a new stake in shares of Turn Therapeutics in the fourth quarter worth approximately $259,000. BlackRock Inc. purchased a new stake in Turn Therapeutics in the second quarter worth $282,000. Finally, Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics during the second quarter valued at approximately $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.